New chemo cocktail aims to boost pancreatic cancer surgery success
NCT ID NCT06821997
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a chemotherapy combination called NALIRIFOX given before surgery to people with borderline resectable pancreatic cancer. The goal is to shrink the tumor enough to allow successful removal and reduce the chance of the cancer coming back. The study will enroll 20 participants and measure how many have a major response in the tumor tissue after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NALIRIFOX (liposomal irinotecan, oxaliplatin, 5-fluorouracil, leucovorin)
What this could lead to
If successful, this approach could make surgery more effective and lower the chance of cancer returning in patients with borderline resectable pancreatic cancer.
What could go wrong
This is a small, early-phase trial with only 20 participants. The chemotherapy combination may cause significant side effects, and it is not yet known if it will improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact